Cargando…

Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer

BACKGROUND: Neoadjuvant immunotherapy with anti-PD-1 was proved promising in resectable non-small cell lung cancer (NSCLC). Immune-related adverse events (irAEs) have been preliminarily implicated their association with treatment efficacy. Here we elucidated the early onset of irAEs associated with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tao, Ye, Li, Xiang, Liu, Bing, Wang, Jia, Lv, Chao, Li, Shaolei, Wang, Yuzhao, Chen, Jinfeng, Yan, Shi, Wu, Nan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225556/ https://www.ncbi.nlm.nih.gov/pubmed/37256186 http://dx.doi.org/10.3389/fonc.2023.1135140

Ejemplares similares

Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer
por: Zhao, Ze-Rui, et al.
Publicado: (2021)

Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
por: He, Wenwu, et al.
Publicado: (2022)

Effectiveness and Safety of Toripalimab Combination Therapies for Patients With Chemo-Resistant Choriocarcinoma
por: Liu, Xiaomei, et al.
Publicado: (2022)

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Lv, Huilai, et al.
Publicado: (2022)

Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer
por: Hu, Yan, et al.
Publicado: (2021)

Toripalimab in advanced biliary tract cancer
por: Li, Wei, et al.
Publicado: (2022)

Multisystem immune-related adverse events due to toripalimab: Two cases-based review
por: Chen, Yanran, et al.
Publicado: (2022)

Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials
por: Li, Xiang, et al.
Publicado: (2021)

Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung
por: Feng, Yuan, et al.
Publicado: (2021)

Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers
por: Wu, Xinyu, et al.
Publicado: (2023)

Severe cumulative skin toxicity during toripalimab combined with vemurafenib following toripalimab alone
por: Zhou, Hong, et al.
Publicado: (2023)

Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC
por: Wang, Yunchao, et al.
Publicado: (2023)

Neoadjuvant immunotherapy and neoadjuvant chemotherapy in resectable non-small cell lung cancer: A systematic review and single-arm meta-analysis
por: Wang, He, et al.
Publicado: (2022)

Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
por: Janssen, Quisette P., et al.
Publicado: (2020)

Editorial: Neoadjuvant treatment for resectable and borderline resectable pancreatic cancer
por: Massani, Marco, et al.
Publicado: (2023)

A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901)
por: Chen, Rui, et al.
Publicado: (2023)

Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial
por: Cao, Yanshuo, et al.
Publicado: (2022)

A phase III study on neoadjuvant chemotherapy versus neoadjuvant toripalimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909)
por: Zheng, Yan, et al.
Publicado: (2021)

Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell Lung cancer
por: Shi, Liang, et al.
Publicado: (2022)

Case Report: Toripalimab Combined With Anlotinib in a Patient With Metastatic Upper Tract Urothelial Carcinoma After Pembrolizumab Failure
por: Zan, Ning, et al.
Publicado: (2022)

Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?
por: Versteijne, Eva, et al.
Publicado: (2022)

Toripalimab in Combination With Induction Chemotherapy and Subsequent Chemoradiation as First-Line Treatment in Patients With Advanced/Metastatic Esophageal Carcinoma: Protocol for a Single-Arm, Prospective, Open-Label, Phase II Clinical Trial (TR-EAT)
por: Wu, Lei, et al.
Publicado: (2022)

Economic evaluation of toripalimab combined with chemotherapy in the treatment of non-small cell lung cancer
por: Wang, Hao, et al.
Publicado: (2023)

Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study
por: Chen, Yongbiao, et al.
Publicado: (2023)

Comparative efficacy and safety of neoadjuvant radiotherapy for patients with borderline resectable, and locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis protocol
por: Lv, Wanrui, et al.
Publicado: (2022)

A phase II, single-centre trial of neoadjuvant toripalimab plus chemotherapy in locally advanced esophageal squamous cell carcinoma
por: Xing, Wenqun, et al.
Publicado: (2020)

Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases
por: Li, Xin, et al.
Publicado: (2022)

Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial
por: Huang, Xiaotao, et al.
Publicado: (2022)

Neoadjuvant Treatment in Resectable Pancreatic Cancer. Is It Time for Pushing on It?
por: Vivarelli, Marco, et al.
Publicado: (2022)

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
por: Ho, Joel, et al.
Publicado: (2022)

Wedge resection plus adequate lymph nodes resection is comparable to lobectomy for small-sized non-small cell lung cancer
por: Ding, Hongdou, et al.
Publicado: (2022)

An open, observational clinical study of neoadjuvant therapy in resectable stage III non-small cell lung cancer
por: Qi, Yuwen, et al.
Publicado: (2023)

Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer
por: Daniello, Lea, et al.
Publicado: (2021)

Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma
por: Trinh, Katherine V., et al.
Publicado: (2020)

Long-Term Efficacy of Neoadjuvant Concurrent Chemoradiotherapy for Potentially Resectable Advanced Siewert Type II and III Adenocarcinomas of the Esophagogastric Junction
por: Tian, Yuan, et al.
Publicado: (2021)

Initial experience of video-assisted thoracic surgery lobectomy after neoadjuvant chemotherapy plus toripalimab in a patient with locally advanced non-small cell lung cancer: a case report
por: Li, Wei, et al.
Publicado: (2022)

Survival Comparison of Neoadjuvant Chemotherapy Followed by Irreversible Electroporation Versus Conversional Resection for Locally Advanced Pancreatic Cancer
por: He, Chaobin, et al.
Publicado: (2021)

Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy
por: Zhao, Ni, et al.
Publicado: (2022)

The Key Clinical Questions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancer—A Review
por: Han, Dan, et al.
Publicado: (2022)

Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non–small cell lung cancer in real world
por: Fang, Min, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n39iqi06l3k7h4njpq79pr2ihd